The Front Room — a clinical regulatory commons
RSS
← Back to feed

Sydnexis low-dose atropine for childhood myopia heads to Oct 30 advisory committee

Sponsor
Sydnexis
Drug
atropine sulfate
Indication
Slowing myopia progression in children 3 years and older
More on Sydnexis ↗ Google News

FDA advisers will meet October 30 to review Sydnexis's NDA for atropine 0.01% eye drops to slow myopia progression in children 3 and older.

Read original at federalregister.gov ↗

From the source

Request Access

Due to aggressive automated scraping of FederalRegister.gov and eCFR.gov, programmatic access to these sites is limited to access to our extensive developer APIs. Please visit

FederalRegister.gov API

documentation or

eCFR.gov API

documentation to learn more about how to access the API.

Your request has been flagged as potentially automated. If you are human user receiving this message, please complete the CAPTCHA (bot test) below and click "Request Access". You may occassionally be asked to complete the CAPTCHA again, this is normal and part of our security measures.

unblock#handleSubmit">

Request Access

An official website of the United States government.

If you experiencing issues with the CAPTCHA or want to request a wider IP range, you can use the "Site Help" button found in the lower, right of this page to make a request.

×

IP Access Help

This contact form is only for IP Access help. Please do not provide confidential information or personal data.

* Your Name

* Email

* How can we help you?

Upload Attachment

* I am requesting technical help.

Loading...

site-feedback#openModal" aria-label="Open site help form">

Site Help

Reproduced from Federal Register — FDA Advisory Committees · view original · public domain or open-licensed government work

Topic Atropine ophthalmic NDA

Drug Watch — recent news on atropine sulfate

Sponsor Watch — recent news on Sydnexis